Press Releases IRLAB Therapeutics AB

Equities

IRLAB A

SE0012675361

Market Closed - Nasdaq Stockholm Other stock markets 11:29:46 2024-05-10 EDT			5-day change	1st Jan Change
13.05 ^SEK	+13.48%		+19.18%	+74.00%

05-08	Transcript : IRLAB Therapeutics AB, Q1 2024 Earnings Call, May 08, 2024
05-07	IRLAB Therapeutics AB and McQuade Center for Strategic Research and Development, LLC Enter into Development Collaboration for IRL757 as Novel Treatment for Apathy	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IRLAB publishes interim report for the period January-March 2024	05-08	AQ
IRLAB Enters a Development Collaboration for IRL757 as a Novel Treatment for Apathy	05-07	AQ
IRLAB has received approval from the Swedish Medical Products Agency to conduct a Phase I study of the drug candidate IRL757	05-06	AQ
IRLAB: Invitation to the interim report for Q1 2024 presentation and webcast	05-06	AQ
IRLAB publishes Annual Report for 2023	04-29	AQ
IRLAB to present at Redeye Investor Forum	04-16	AQ
IRLAB receives minutes from End-of-Phase 2 meeting confirming alignment with the FDA on the Phase III program for mesdopetam	03-25	AQ
IRLAB receives minutes from End-of-Phase 2 meeting confirming alignment with the FDA on the Phase III program for mesdopetam	03-22	AQ
IRLAB Therapeutics : mesdopetam displays antipsychotic properties in an advanced model of Parkinson's disease psychosis	03-19	PU
IRLAB’s mesdopetam displays antipsychotic properties in an advanced model of Parkinson’s disease psychosis	03-19	AQ
IRLAB to present at Life Science-dagen in Gothenburg and have a fireside chat with ABG	02-29	AQ
IRLAB to present at the Bayes@Lund 2024 Conference in Lund, Sweden on March 7	02-28	AQ
IRLAB to present clinical and preclinical data at the AD/PD™ 2024: 18th International Conference on Alzheimer’s & Parkinson’s Diseases	02-27	AQ
IRLAB has completed a successful End-of-Phase 2 meeting with the FDA on the design of the Phase III program for mesdopetam	02-22	AQ
IRLAB's pioneering Phase IIb study with pirepemat, React-PD, provides new insights in specific Parkinson's patient population and enables a data driven prediction of study timelines	02-07	AQ
IRLAB publishes year-end report for the period January-December 2023	02-07	AQ
IRLAB’s pioneering Phase IIb study with pirepemat – React-PD – provides new insights in specific Parkinson’s patient population and enables a data driven prediction of study timelines	02-06	AQ
IRLAB, Invitation to the Year-end Report 2023 presentation and webcast	02-01	AQ
IRLAB: Invitation to the Year-end Report 2023 presentation and webcast	01-31	AQ
IRLAB is granted an end-of-Phase 2 meeting with the FDA for the Phase III-ready mesdopetam program	01-03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases IRLAB Therapeutics AB

Equities

IRLAB A

SE0012675361

Press Releases

Filters